34026 Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Room #3122, Bethesda, MD 20817 

(Telephone Conference Call). 

Contact Person: Brenda Lange-Gustafson, 

PhD,Scientific Review 

Administrator,Scientific Review 

Program,Division of Extramural 

Activities,National Institutes of Health,6700B 

Rockledge Drive, MSC 7616,Bethesda, MD 

20892,301–496–

2550,bgustafson@niaid.nih.gov. 

Name of Committee: Microbiology, 

Infectious Diseases and AIDS Initial Review 

Group, Acquired Immunodeficiency 

Syndrome Research Review Committee, 

AIDS Research Review Committee (July 

2007). 

Date: July 10, 2007. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Bethesda, MD 20817 (Telephone Conference 

Call). 

Contact Person: Erica L. Brown, 

PhD,Scientific Review 

Administrator,Scientific Review 

Program,Division of Extramural 

Activities,National Institutes of Health/ 

NIAID,6700B Rockledge Drive, MSC 7616, 

Bethesda, MD 20892–7616,301–451–

2639,ebrown@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.93.855, Allergy, Immunology, 

and Transplantation Research;93.856, 

Microbiology and Infectious Diseases 

Research,National Institutes of Health, HHS) 

Dated: June 12, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3013 Filed 6–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Vision 

Research. 

Date: June 26, 2007. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Jerry L. Taylor, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5202, 

MSC 7846, Bethesda, MD 20892, (301) 435–

1175, taylorje@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Transporters, Receptors and Scaffolds. 

Date: June 27, 2007. 

Time: 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Jonathan K. Ivins, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4040A, 

MSC 7806, Bethesda, MD 20892, (301) 594–

1245, ivinsj@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, KNOD/ 

CASE Member SEP. 

Date: June 29, 2007. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Steven H. Krosnick, MD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3158, 

MSC 7770, Bethesda, MD 20892, (301) 435–

1712, krosnics@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Fellowships: Technology Development. 

Date: July 9–10, 2007. 

Time: 7:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Marc Rigas, PhD, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 5158, MSC 7849, 

Bethesda, MD 20892, (301) 402–1074, 

rigasm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: Brain Disorders and Clinical 

Neuroscience. 

Date: July 11, 2007. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Alexander Yakovlev, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5206, 

MSC 7846, Bethesda, MD 20892, (301) 435–

1254, yakovleva@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Substance 

Abuse, Non-Injection Drug Use and HIV/ 

AIDS. 

Date: July 16–18, 2007. 

Time: 8 a.m. to 8 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Jose H. Guerrier, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, (301) 435–

1137, guerriej@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflicts for BMRD. 

Date: July 16, 2007. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Karin F. Helmbers, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3166, 

MSC 7770, Bethesda, MD 20892, (301) 435–

1017, helmersk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Physiology 

and Pathology of Organ Systems. 

Date: July 17, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate Hotel, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Bukhtiar H. Shah, PhD, 

DVM, Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 4213, MSC 7802, Bethesda, MD 20892, 

(301) 435–1233, shahb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Brain 

Disorders and Clinical NeuroscienceMembers. 

Date: July 18, 2007. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 


rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices 34027 

Contact Person: Jay Joshi, PhD, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 5184, MSC 7846, 

Bethesda, MD 20892, (301) 435–1184, 

joshij@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Brain 

Disorders and Clinical NeuroscienceMembers. 

Date: July 19, 2007. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Jay Joshi, PhD, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 5184, MSC 7846, 

Bethesda, MD 20892, (301) 435–1184, 

joshij@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Xenopus 

Genetics and Genomics. 

Date: July 23–24, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Barbara J. Thomas, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2218, 

MSC 7890, (301) 435–0603, 

bthomas@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Small 

Business: Arthritis, Connective Tissue and 

Skin Sciences. 

Date: July 23, 2007. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate Hotel, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Harold M. Davidson, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4222, 

MSC 7814, Bethesda, MD 20892, (301) 435–

1776, davidsoh@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Stem Cells, 

Neuron Migration and Guidance. 

Date: July 23, 2007. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Carol Hamelink, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5040H, 

MSC 7850, Bethesda, MD 20892, (301) 451–

1328, hamelinc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Small 

Business: Digestive Sciences and 

Bioengineering. 

Date: July 23, 2007. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Bonnie L. Burgess-Beusse, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2191C, 

MSC 7818, Bethesda, MD 20892, (301) 435–

1783, beusseb@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.847–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 12, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3014 Filed 6–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Anti-Mesothelin Antibodies 

Useful for Immunological Assays 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent Application 

No. 60/681,104, filed May 12, 2005, 

entitled ‘‘Anti-Mesothelin Antibodies 

Useful For Immunological Assays’’ [E–

015–2005/0–US–01] and PCT 

Application No. PCT/US2006/018502, 

filed May 11, 2006, entitled ‘‘AntiMesothelin Antibodies Useful For 

Immunological Assays’’ [E–015–2005/0–

PCT–02] to Cambridge Antibody 

Technology, Ltd., which has offices in 

Cambridge, United Kingdom. The patent 

rights in these inventions have been 

assigned to the United States of 

America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the use 

of the SSIP immunoconjugate and 

variants thereof for the treatment of 

mesothelin expressing cancers. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

August 20, 2007 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Jesse S. Kindra, J.D., 

M.S., Technology Licensing Specialist, 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435–

5559; Facsimile: (301) 402–0220; E-mail: 

kindraj@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: This 

technology relates to anti-mesothelin 

antibodies with a particularly high 

affinity for mesothelin and the ability to 

be used in immunological assays for 

detecting the presence of mesothelin in 

biological samples. The anti-mesothelin 

antibodies are well-suited for the 

diagnosis and treatment of cancers of 

the ovary, stomach, squamous cells, 

mesotheliomas and other malignant 

cells expressing mesothelin. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR Part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: June 11, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer,Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–11828 Filed 6–19–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

The Critical Infrastructure Partnership 

Advisory Council (CIPAC) 

AGENCY: Directorate for National 

Protection and Programs, DHS. 

ACTION: Committee management; update 

on CIPAC committee membership. 


rwilkins on PROD1PC63 with NOTICES